Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
about
A pretargeting system for tumor PET imaging and radioimmunotherapyGerman Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an updateMedullary thyroid cancer: monitoring and therapy.Notch in the development of thyroid C-cells and the treatment of medullary thyroid cancer.Expression of HIF-1α in medullary thyroid cancer identifies a subgroup with poor prognosis.Adjuvant external beam radiation for medullary thyroid carcinoma.RET mutations in a large indian family with medullary thyroid carcinoma.Pretargeted radioimmunotherapy for hematologic and other malignanciesCabozantinib in progressive medullary thyroid cancer.Update on thyroid cancer treatment.The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report.Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.Testicular and inguinal lymph node metastases of medullary thyroid cancer: a case report and review of the literature.Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.Treating medullary thyroid cancer in the age of targeted therapy.Identification of occult metastases of medullary thyroid carcinoma by pentagastrin-stimulated intravenous calcitonin sampling followed by targeted surgery.Kinase inhibitors for advanced medullary thyroid carcinoma.MEDULLARY THYROID CANCER THAT STAINS NEGATIVE FOR CA 19-9 HAS DECREASED METASTATIC POTENTIAL.Cancer Imaging and Therapy with Bispecific Antibody Pretargeting.The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancerTumor suppressor role of notch1 and raf-1 signaling in medullary thyroid cancer cells.Improvement of radioimmunotherapy using pretargeting.Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer.Current understanding and management of medullary thyroid cancer.2012 European thyroid association guidelines for metastatic medullary thyroid cancer.Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer.Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis.Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma.The effect of extent of surgery and number of lymph node metastases on overall survival in patients with medullary thyroid cancer.Vandetanib for the treatment of thyroid cancer.Medullary thyroid cancer--current treatment strategy, novel therapies and perspectives for the future.Disulfide bonds in amyloidogenesis diseases related proteins.Clinical challenges with calcitonin-negative medullary thyroid carcinoma.Surgical management of medullary thyroid carcinoma.A diagnostic dilemma: a young boy with loss of weight, pulmonary infiltrates and cervical lymphadenitis.Extent of surgery in clinically evident but operable MTC - when is central and/or lateral lympadenectomy indicated?Treatment of advanced medullary thyroid cancer.A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy.Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature.
P2860
Q28087820-082B30ED-7981-4B8A-B198-E39E894BDB43Q30317867-C5E998BF-715E-4A48-9656-C65435DE781BQ33587821-AB8B700D-F6A6-4D85-AF4E-F6E88CB132D0Q33591999-0E4F9C53-4C0D-40B4-83BC-68E77839B6E1Q33680709-2C12F329-A222-4875-A992-B2F51B34121DQ33709832-A3C375F1-5F6A-465A-BBA4-55EC37840527Q34015508-F390D51A-880E-4C65-8491-BADD347DDCE7Q34069272-E917CD8E-8B1F-4E35-A084-FC34D0BD984DQ34113941-0EB9A2CA-E1CC-41A8-8AE9-67D7303CC9B3Q34185084-E40002A0-A163-4814-B6C5-D9004D024C5BQ34310219-2BFC4540-DA7B-4BC5-947E-F742906AE7C9Q34331382-650777D3-B711-48AE-AD0A-2742FF92A18FQ34468665-DF4F57AA-2249-4392-9439-2E41AAECAF59Q34739831-4E1E10D4-1AF0-4F67-96E7-7E9F59970759Q35396089-E5589D17-31C0-42AC-85F3-FB8691A5141FQ35509932-FB61EB18-9604-4D58-AFA2-037A374EF333Q35768791-DA8A1936-34A4-492F-A659-612121D52BD6Q35895485-8058D148-CB32-4C0A-9D9E-CCD39832E171Q36069550-44EA9E83-0224-4678-AC09-6F2B7060A18EQ36082355-8D8E073A-4EDC-4C89-9A3F-2B82ABDC6277Q36164034-1D393544-04E3-46BD-A129-7B15C95617B2Q36790872-D39AC1B8-9BF1-41CD-978E-C4038DF50A0BQ36941931-EB2946EB-7013-49C9-BB48-544161751CDDQ37179234-740DF870-5EF4-4D59-A1B8-BD259B54BF23Q37247181-6809A2DB-71CC-4CD4-87EF-812ED1E5FA31Q37290840-346DDE5E-82F3-469A-9DAF-D15FEA217E9EQ37401654-6078D57E-88AF-4777-86AF-42E984493787Q37402609-15EDCA88-BC3A-40F0-B7F7-90EE0ADF6677Q37431034-34D75725-1ADE-42D3-A709-719EA8EC1FA4Q37554717-507213A5-A1FE-40D3-BE32-04DE4E312A83Q37967112-7B4D3CCF-D673-446F-B7E8-4515AC2139E9Q38046525-19A18A29-F019-4F5B-B2ED-E8FADAE16F9BQ38113990-3167B6E8-723E-44EA-9711-E5D39C0D3207Q38820275-E824FEE9-BFDF-4297-9521-5C3757AF259BQ38837195-404F3650-7107-47D6-87CA-436A94B3649FQ40232872-6A5B4C29-A359-41D7-BAE9-140F45D32870Q41042731-DB9ABA46-6473-42B8-B6CE-09554335F93CQ41043040-0C71F461-8929-4125-BEA9-0E1FEBD58DA5Q41718682-97BA1C48-7413-4F0A-93C4-E8CB7D45B083Q47137441-5B1636B9-ECF0-45A4-AF3E-73475D69A255
P2860
Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Prognostic impact of serum cal ...... h medullary thyroid carcinoma.
@ast
Prognostic impact of serum cal ...... h medullary thyroid carcinoma.
@en
Prognostic impact of serum cal ...... h medullary thyroid carcinoma.
@nl
type
label
Prognostic impact of serum cal ...... h medullary thyroid carcinoma.
@ast
Prognostic impact of serum cal ...... h medullary thyroid carcinoma.
@en
Prognostic impact of serum cal ...... h medullary thyroid carcinoma.
@nl
prefLabel
Prognostic impact of serum cal ...... h medullary thyroid carcinoma.
@ast
Prognostic impact of serum cal ...... h medullary thyroid carcinoma.
@en
Prognostic impact of serum cal ...... h medullary thyroid carcinoma.
@nl
P50
P356
P1476
Prognostic impact of serum cal ...... h medullary thyroid carcinoma.
@en
P2093
GTE Study Group
Jean-François Chatal
P304
P356
10.1210/JC.2005-0044
P407
P577
2005-08-09T00:00:00Z